 Iradimed NASDAQ:IRMD was upgraded by ValuEngine from a hold rating to a buy rating in a report issued on Friday, ValuEngine reports. A number of other research analysts have also commented on the company. Roth Capital lowered their price objective on Iradimed from 32.00 to 30.00 in a report on Tuesday. Zacks Investment Research upgraded ... 